Monocl hires Guy Bowman as Vice President Sales

Industry veteran to lead global sales and US Expansion! We are happy to announce today that Guy Bowman, an experienced sales leader with a proven track record, has joined Monocl's executive team as Vice President of Sales.

Read more

The novel space of CAR macrophages outlined

Combining CAR with macrophages, not T-cells, is a disruptive approach to immunotherapy that leverage advances in macrophage biology and chimeric antigen receptor to better take out solid tumors. This week we shows you the established opinion leaders and top institutions to have on your radar.

Read more

Monocl nominated as one of the finalists in the Serendipity Challenge 2018!

Monocl nominated as one of the finalists in the Serendipity Challenge 2018!

Read more

Leaders within oncoloytic virotherapy

Oncolytic virotherapy represents an exciting new area of cancer treatment. The treatment modality exploits a virus’s ability to selectively replicate and kill tumor tissue while stimulating a patient-specific immune response against cancer. Interest in the field is high following significant deals and developments by actors such as Pfizer, Celgene and Amgen.

Read more

Key stakeholders, rising stars and top sponsors in influenza research

New novel leaps forward has made it possible to develop drugs that can surpress replication of the flu virus within 24 hours. Many groups are now looking to develop universal flu vaccines that can hold off a variety of flu strains for multiple seasons. This week, we outline the key stakeholder in influenza research.

Read more

Key stakeholders, rising stars and top targets in Gene therapy for haemophilia

Gene therapy has long been the Holy Grail for treatment of haemophilia. This week we take a look at the top researchers, rising stars and institutions in this space.

Read more